Spotlight Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 32

Employees

  • Latest Deal Type
  • M&A

Spotlight Therapeutics General Information

Description

Operator of a biotechnology platform intended to develop a new class of therapeutics by direct cell-targeted in vivo gene editing. The company's platform delivers CRISPR nuclease effectors to selected cell types in vivo, with initial programs in immuno-oncology, ophthalmology, and hematology, and is building a pipeline of immuno-oncology programs addressing pre-clinically validated, but classically undruggable, intracellular gene targets in addition to differentiated CRISPR-validated monogenic disease targets of the eye, enabling healthcare providers to address the limitations of the cell, viral, and nanoparticle-mediated delivery for gene editing. .

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3980 Trust Way
  • Hayward, CA 94545
  • United States
Primary Industry
Biotechnology
Acquirer
Corporate Office
  • 3980 Trust Way
  • Hayward, CA 94545
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spotlight Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 04-Jan-2022 Completed Pre-Clinical Trials
4. Early Stage VC (Series A2) 30-Nov-2020 Completed Startup
3. Early Stage VC (Series A1) 25-Sep-2019 Completed Startup
2. Seed Round 02-Jan-2018 $7.27M $7.27M Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Spotlight Therapeutics’s complete valuation and funding history, request access »

Spotlight Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A2
Series A1 6,388,886 $0.000100 $0.09 $1.08 $1.08 1x $1.08 13.17%
Series A 8,133,334 $0.000100 $0.08 $1 $1 1x $1 16.77%
To view Spotlight Therapeutics’s complete cap table history, request access »

Spotlight Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to develop a new class of therapeutics by direct cell-targeted in vivo gen
Biotechnology
Hayward, CA
32 As of 2023

Rockville, MD
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spotlight Therapeutics Competitors (96)

One of Spotlight Therapeutics’s 96 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Amber (Biotechnology) Venture Capital-Backed San Francisco, CA
MeiraGTx Formerly VC-backed New York, NY
ERS Genomics Corporate Backed or Acquired Dublin, Ireland
You’re viewing 5 of 96 competitors. Get the full list »

Spotlight Therapeutics Patents

Spotlight Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025038950-A1 Cell-penetrating peptide compositions and uses thereof Inactive 16-Aug-2023
WO-2024226822-A2 Cd11a tage compositions and uses thereof Inactive 26-Apr-2023
WO-2024226822-A3 Cd11a tage compositions and uses thereof Inactive 26-Apr-2023
WO-2024077184-A2 Cd11a tage compositions and uses thereof Inactive 05-Oct-2022
WO-2024077184-A3 Cd11a tage compositions and uses thereof Inactive 05-Oct-2022 C07K16/2818
To view Spotlight Therapeutics’s complete patent history, request access »

Spotlight Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spotlight Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
DNA Capital (Investor) Venture Capital Minority
EPIQ Capital Group Family Office Minority
Emerson Collective Impact Investing Minority
Foothill Ventures Venture Capital Minority
GV Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Spotlight Therapeutics FAQs

  • When was Spotlight Therapeutics founded?

    Spotlight Therapeutics was founded in 2017.

  • Where is Spotlight Therapeutics headquartered?

    Spotlight Therapeutics is headquartered in Hayward, CA.

  • What is the size of Spotlight Therapeutics?

    Spotlight Therapeutics has 32 total employees.

  • What industry is Spotlight Therapeutics in?

    Spotlight Therapeutics’s primary industry is Biotechnology.

  • Is Spotlight Therapeutics a private or public company?

    Spotlight Therapeutics is a Private company.

  • What is Spotlight Therapeutics’s current revenue?

    The current revenue for Spotlight Therapeutics is .

  • How much funding has Spotlight Therapeutics raised over time?

    Spotlight Therapeutics has raised $66.5M.

  • Who are Spotlight Therapeutics’s investors?

    DNA Capital (Investor), EPIQ Capital Group, Emerson Collective, Foothill Ventures, and GV are 5 of 9 investors who have invested in Spotlight Therapeutics.

  • Who are Spotlight Therapeutics’s competitors?

    Regenxbio, Genetix Biotherapeutics, Amber (Biotechnology), MeiraGTx, and ERS Genomics are some of the 96 competitors of Spotlight Therapeutics.

  • Who acquired Spotlight Therapeutics?

    Spotlight Therapeutics was acquired by Stipple Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process